Ultragenyx Pharmaceutical, Inc. (RARE)
22.51
-0.70
(-3.02%)
USD |
NASDAQ |
Jan 09, 16:00
22.71
+0.20
(+0.89%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly): 207.61M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.693B |
| CorMedix, Inc. | 5.098M |
| Amicus Therapeutics, Inc. | 23.42M |
| Geron Corp. | 21.07M |
| Insmed, Inc. | 186.42M |